My watch list

3,4-Diaminopyridine

This article or section is in need of attention from an expert on the subject.

WikiProject Medicine may be able to help recruit one.
If a more appropriate WikiProject or portal exists, please adjust this template accordingly.


3,4-Diaminopyridine
Systematic (IUPAC) name
3,4-Diaminopyridine
Identifiers
CAS number	54-96-6
ATC code	?
PubChem	?
Chemical data
Formula	C₅H₇N₃
Mol. mass	109.13
Pharmacokinetic data
Bioavailability	30% ^[1],^[2]
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status	Phase III
Routes	Oral

3,4-Diaminopyridine is an experimental drug used in the treatment of Lambert-Eaton Syndrome. In Lambert-Eaton Syndrome, acetylcholine release is inhibited as antibodies meant to target characteristic cancers target Ca²⁺ channels on the prejunctional membrane instead. 3,4-Diaminopyridine works by blocking potassium channel efflux in nerve terminals so that action potential duration is increased. Ca²⁺ channels can then be open for longer time and allow greater acetylcholine release to stimulate muscle at end plate.

Product highlight

References

^ AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. (2001). "Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthena gravis or Lambert-Eaton myasthenic syndrome: summary statement". Muscle Nerve 24: 1236-1238.
^ Lundh H, Nilsson O, Rosen I, Johansson S. (1993). "Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.". Acta Neurol Scand 88: 136-140.
^ Judge S, Bever C (2006). "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment". Pharmacol. Ther. 111 (1): 224-59. PMID 16472864.